Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC)

BACKGROUND: Treatment options for mRCC have evolved to include VEGF targeted therapies (VEGF-TT), immune checkpoint inhibitors (ICIs), or combinations of both. However, clinical responses to systemic therapies in mRCC remain largely unpredictable and robust biomarkers are still lacking. The interact...

Descripción completa

Detalles Bibliográficos
Autores principales: Saad, Eddy, Labaki, Chris, Saliby, Renée-Maria, Bakouny, Ziad, Song, Li, Wall, McKenzy, Pan, Wenting, Semaan, Karl, Eid, Marc, Gwo-Shu, Mary Lee, Braun, David, Liu, Xiaole Shirley, Choueiri, Toni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Oral Abstract Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445570/
http://dx.doi.org/10.1093/oncolo/oyad216.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445570/
http://dx.doi.org/10.1093/oncolo/oyad216.007

Ejemplares similares